Associated Papers
Management of autosomal dominant hypocalcemia type 1: Literature review and clinical practice recommendations.
De Coster T et al.
Journal of Endocrinological Investigation, 2025
Characterization of quinazolinone calcilytic therapy for autosomal dominant hypocalcemia type 1 (ADH1).
Hannan FM et al.
The Journal of Biological Chemistry, 2025
An activating calcium-sensing receptor variant with biased signaling reveals a critical residue for Gα11 coupling.
Benson MR et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 2025
CASRdb: A Publicly Accessible Comprehensive Database for Disease-Associated Calcium-Sensing Receptor Variants.
Charoenngam N et al.
The Journal of Clinical Endocrinology and Metabolism, 2025
Cell Surface Calcium-Sensing Receptor Heterodimers: Mutant Gene Dosage Affects Ca2+ Sensing but Not G Protein Interaction.
Goolam MA et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research, 2022
Differential parathyroid and kidney Ca2+-sensing receptor activation in autosomal dominant hypocalcemia 1.
van Megen WH et al.
Ebiomedicine, 2022
Calcilytic NPSP795 Increases Plasma Calcium and PTH in an Autosomal Dominant Hypocalcemia Type 1 Mouse Model.
Hannan FM et al.
Jbmr Plus, 2020
International Union of Basic and Clinical Pharmacology. CVIII. Calcium-Sensing Receptor Nomenclature, Pharmacology, and Function.
Leach K et al.
Pharmacological Reviews, 2020
The excretion of uromodulin is modulated by the calcium-sensing receptor.
Tokonami N et al.
Kidney International, 2018
Homozygous Calcium-Sensing Receptor Polymorphism R544Q Presents as Hypocalcemic Hypoparathyroidism.
Cavaco BM et al.
The Journal of Clinical Endocrinology and Metabolism, 2018
Mutant Mice With Calcium-Sensing Receptor Activation Have Hyperglycemia That Is Rectified by Calcilytic Therapy.
Babinsky VN et al.
Endocrinology, 2017
Gα11 mutation in mice causes hypocalcemia rectifiable by calcilytic therapy.
Gorvin CM et al.
Jci Insight, 2017
Disorders of the calcium-sensing receptor and partner proteins: insights into the molecular basis of calcium homeostasis.
Hannan FM et al.
Journal of Molecular Endocrinology, 2016
Activating Calcium-Sensing Receptor Mutations: Prospects for Future Treatment with Calcilytics.
Mayr B et al.
Trends in Endocrinology and Metabolism: Tem, 2016
The Calcilytic Agent NPS 2143 Rectifies Hypocalcemia in a Mouse Model With an Activating Calcium-Sensing Receptor (CaSR) Mutation: Relevance to Autosomal Dominant Hypocalcemia Type 1 (ADH1).
Hannan FM et al.
Endocrinology, 2015
New functional aspects of the extracellular calcium-sensing receptor.
Toka HR
Current Opinion in Nephrology and Hypertension, 2014
A novel mutation of the primary protein kinase C phosphorylation site in the calcium-sensing receptor causes autosomal dominant hypocalcemia.
Lazarus S et al.
European Journal of Endocrinology, 2011
Inherited disorders of calcium homeostasis.
Ramasamy I
Clinica Chimica Acta; International Journal of Clinical Chemistry, 2008
Activating calcium-sensing receptor mutation in the mouse is associated with cataracts and ectopic calcification.
Hough TA et al.
Proceedings of the National Academy of Sciences of the United States of America, 2004